|drug1517||Hydroxychloroquine , Sofosbuvir, daclatasvir Wiki||0.71|
|drug286||Ascorbic Acid Wiki||0.35|
|D045169||Severe Acute Respiratory Syndrome NIH||0.06|
There are 2 clinical trials
The objective of this study is to evaluate the efficacy of oral favipiravir plus standard of care treatment (SOC) compared with placebo plus SOC in reducing the duration of shedding of SARS-CoV2 virus in patients with mild or asymptomatic COVID-19.
Description: Time in days from randomization to the first two negative results of nasal and/or oropharyngeal swab.Measure: Time until cessation of oral shedding of SARS-CoV-2 virus Time: Up to 28 days
Description: Viral load (nucleic acid) will be assessed by RT-PCR over time.Measure: Sars-CoV-2 viral load Time: Up to 28 days
Description: Clinical worsening will be determined by clinician assessment.Measure: Count of participants with clinical worsening of COVID-19 disease Time: Up to 28 days
Description: This outcome will be assessed in patient who are asymptomatic of COVID-19 infection at the time of enrollmentMeasure: Count of participant with absence of development of any symptoms Time: Up to 28 days
Description: Cmax is a pharmacokinetic parameter that measures the maximum concentration of drug in plasma.Measure: Cmax of favipiravir Time: Days 1 and 10 (samples taken 30 minutes prior to and 1 hour following favipiravir administration)
Description: Cmin is a pharmacokinetic parameter that measures the minimum concentration of drug in plasma.Measure: Cmin of favipiravir Time: Days 1 and 10 (samples taken 30 minutes prior to and 1 hour following favipiravir administration)
COVID 19 which started from a zoonotic transmission related to crowded markets was confirmed to have a high potential for transmission to close contacts on 20 January 2020 by the National Health Commission of China and it was announced as a pandemic by the WHO on 11 March 2020. There is currently no clinically proven specific antiviral agent available for SARS-CoV-2 infection. Supportive treatment, including oxygen therapy, conservation fluid management, and broad-spectrum antibiotics to cover secondary bacterial infection, remains the most important management strategy. Interestingly, sofosbuvir has recently been proposed as an antiviral for the SARS-CoV-2 based on the similarity between the replication mechanisms of the HCV and the coronaviruses. Aim of the study is to assess the safety and efficacy of of the addition of HCV treatment to the standard regimen for the treatment of patients who are candidates to receive Hydroxy Chloroquine according to Egyptian MOHP protocol
Description: virological cure using the triple therapy as compared to mono hydroxychloroquine treatment..Measure: Virological cure Time: 28 days
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports